Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

Abstract Background Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patien...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Farastuk Bozorgmehr, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Jonas Kuon, Martin Maenz, Peter E. Huber, Laila König, Meinhard Kieser, Juergen Debus, Michael Thomas, Stefan Rieken
Format: Artigo
Jezik:Inglês
Izdano: BMC 2019-11-01
Serija:BMC Cancer
Teme:
Non-small cell lung cancer
Immunotherapy
Radioimmunotherapy
Abscopal effect
PD-1
Nivolumab
Online pristup:http://link.springer.com/article/10.1186/s12885-019-6205-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items